TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05384496: Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$739,200

Rescue Site Savings

+$508,200

Unlock Full NCT05384496 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05384496 Rescue Dossier →